Academic literature on the topic 'Viande – virologie'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Viande – virologie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Viande – virologie"

1

Ferrer, Pedro E., Mark Bloch, Norman Roth, et al. "A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes." International Journal of STD & AIDS 29, no. 3 (2017): 300–305. http://dx.doi.org/10.1177/0956462417730474.

Full text
Abstract:
The most common reasons for switching HIV-1 therapy in patients with virologic suppression are treatment regimen simplification and resolving tolerability issues. Single-pill regimens that include an integrase inhibitor are recommended options. A retrospective clinical audit was performed to determine the motivations for switching to dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC) at high HIV-caseload general practice clinics in Australia. The most common reasons for switching from a prior suppressive therapy to DTG/ABC/3TC were simplification of regimen, resolving toxicity/intolerance and
APA, Harvard, Vancouver, ISO, and other styles
2

ROSE, Nicolas, and Marie-Frédérique LE POTIER. "L’épizootie de Peste Porcine Africaine : virologie, épidémiologie et perspectives de contrôle." INRAE Productions Animales 33, no. 2 (2020): 65–80. http://dx.doi.org/10.20870/productions-animales.2020.33.2.3857.

Full text
Abstract:
La Peste Porcine Africaine (PPA) est une maladie infectieuse émergente des suidés domestiques et sauvages. Cette maladie contagieuse entre suidés, non transmissible à l’Homme, est à l’origine d’un syndrome hémorragique souvent fatal chez les porcs domestiques et les sangliers. L'épizootie qui sévit actuellement en Europe et en Asie a débuté en Géorgie en 2007. La souche virale impliquée, très virulente, appartenant au génotype II, est très résistante dans les viandes et l’environnement. Toutes les souches isolées en Europe comme en Asie dérivent d’une même introduction, même si le virus a évol
APA, Harvard, Vancouver, ISO, and other styles
3

Selvanayagam, Stephen, Amy Kang, and David Ha. "Baloxavir Marboxil: A New Antiviral for Acute Influenza." Journal of Contemporary Pharmacy Practice 66, no. 4 (2020): 33–38. http://dx.doi.org/10.37901/jcphp19-00004.

Full text
Abstract:
Baloxavir is a newly approved, single-dose, oral influenza antiviral indicated for acute uncomplicated influenza in patients 12 years and older if symptomatic for less than 48 hours. The purpose of this article is to review currently available literature on the mechanism of action, pharmacokinetics, safety, and clinical and virologic efficacy of baloxavir. Its novel mechanism of action prevents influenza replication by targeting the viral cap-dependent endonuclease enzyme. In clinical trials baloxavir was shown to be superior to placebo and comparable to oseltamivir with regard to time to alle
APA, Harvard, Vancouver, ISO, and other styles
4

Duggan, Joan, and Eric Sahloff. "Clinical outcomes associated with once daily ritonavir-boosted darunavir in HIV infected patients harboring single or multi-class resistant virus." Open Forum Infectious Diseases 4, suppl_1 (2017): S432. http://dx.doi.org/10.1093/ofid/ofx163.1092.

Full text
Abstract:
Abstract Background Limited data exist on the use of a potent boosted protease inhibitor plus <2 active nucleotide reverse transcriptase inhibitors without use of additional classes of ART in treatment experienced patients with background resistance. We evaluated the clinical outcomes in HIV-infected patients harboring single or multi-class resistant virus (NRTI ± PI and/or NNRTI) treated with once daily darunavir/ritonavir (DRV/r) plus tenofovir/emtracitabine (TDF/FTC). Methods This was a single-center, retrospective chart review of HIV-1 infected patients harboring single or multi-cla
APA, Harvard, Vancouver, ISO, and other styles
5

Rolle, Charlotte-Paige M., Omar Marquez, Vu Nguyen, Federico Hinestrosa, and Edwin DeJesus. "2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment." Open Forum Infectious Diseases 6, Supplement_2 (2019): S859—S860. http://dx.doi.org/10.1093/ofid/ofz360.2160.

Full text
Abstract:
Abstract Background Darunavir (DRV) is a well-tolerated, potent protease inhibitor used once-daily in patients with no DRV resistance-associated mutations (RAMs) and twice-daily in those with DRV RAMs. Treatment guidelines encourage use of once-daily regimens to optimize patient adherence, convenience and tolerability. Several studies suggest that once-daily DRV retains efficacy in the setting of 1–2 DRV RAMs whereas 3 or more DRV RAMs (with multiple background PI RAMs) is needed for DRV resistance. Currently, there is little clinical data to support the long-term use of once-daily DRV in pati
APA, Harvard, Vancouver, ISO, and other styles
6

Quinn, Thomas P., and Duane P. Grandgenett. "Avian retrovirus integration protein: Structure-functional analysis of viable mutants." Virology 173, no. 2 (1989): 478–88. http://dx.doi.org/10.1016/0042-6822(89)90560-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Linder, Stig, Mats Nilsson, Ingrid Martens, and Göran Magnusson. "A viable mouse polyomavirus mutant without immortalizing or transforming activities." Virology 179, no. 1 (1990): 78–86. http://dx.doi.org/10.1016/0042-6822(90)90276-w.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Imamura, Daisuke, Tamaki Mizuno, Shin-ichi Miyoshi, and Sumio Shinoda. "Stepwise changes in viable but nonculturableVibrio choleraecells." Microbiology and Immunology 59, no. 5 (2015): 305–10. http://dx.doi.org/10.1111/1348-0421.12246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Saha, Kunal, Y. C. Lin, and P. K. Y. Wong. "A simple method for obtaining highly viable virus from culture supernatant." Journal of Virological Methods 46, no. 3 (1994): 349–52. http://dx.doi.org/10.1016/0166-0934(94)90005-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schranz, P., H. Neidhardt, C. H. Schroder, and H. C. Kaerner. "A viable HSV-1 mutant deleted in two nonessential major glycoproteins." Virology 170, no. 1 (1989): 273–76. http://dx.doi.org/10.1016/0042-6822(89)90377-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Viande – virologie"

1

Temmam, Sarah. "Caractérisation des communautés virales de vecteurs & réservoirs de zoonoses : exemples des culicoïdes et de la viande de brousse." Thesis, Aix-Marseille, 2016. http://www.theses.fr/2016AIXM5004/document.

Full text
Abstract:
Les zoonoses constituent plus des deux tiers des pathologies virales qui concernent l’homme. Le développement et la démocratisation des outils de métagénomique en font de bons outils d’inventaire et de surveillance de virus potentiellement émergents.Dans un premier temps j’ai développé et validé un protocole expérimental de purification des viromes à ARN qui permettait le maintien de l’infectivité des particules virales. Ce protocole a ensuite été appliqué pour caractériser les communautés virales d’arthropodes hématophages et de prélèvements de faune sauvage. J’ai par la suite réalisé l’inven
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Viande – virologie"

1

Oliver, Anthony R. "Virological Diagnostic Methods." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0016.

Full text
Abstract:
Every clinical virologist must step back and ask what the aim of diagnostics is, in general, i.e. the ‘who/ what/ when/ where’ questions. Broadly, the clinical virologists of today must answer a limited set of questions because that is what current technology allows: ● Is this person currently infected with a virus? ● Has this person ever been infected/ exposed to a virus? ● This person has a confirmed virus infection— how is it progressing with or without intervention? ● From whom was this virus infection contracted? However, currently many questions remain remarkably difficult to answer with existing diagnostics. Increasingly the focus of diagnostics is moving from interest solely in the virus itself to how a given virus interacts with a given host pre/ post infection, e.g. HIV host co- receptor testing. Nearly all virological diagnostic methods rely on two fundamental technical principles— target and signal amplification, which both allow the visualization of virus- specific antigen/antibody or nucleic acid. Luckily, some clinical samples, e.g. stool, do not require amplification in order to detect significant virus infections, but even in these situations it is impossible to visualize the presence of viruses or their host antibodies without highly specialized equipment and chemistry. Most viruses are < 200nm in size, and therefore it is impossible to resolve virus particles even with the best optical microscopes. Nearly all of the methodologies detect surrogate markers. It is of note that viable virus numbers do not equal nucleic acid copies, which do not equal virus capsids visible by electron microscopy: these are apples and elephants when trying to compare their quantity. Diagnostic technology operates in two phases or realms; detection or screening, and characterization. For example, asking if a patient has an Influenza A virus infection, followed by asking what is the haemagglutinin/neuraminidase type (e.g. H1N1).
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!